Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Furuya

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Science Advances|September 7, 2019
Biogeochemical controls of surface ocean phosphateAdam C Martiny, Michael W Lomas, Weiwei Fu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 15, 2020
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world settingTakuya Sho, Goki Suda, Koji Ogawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.
Science Advances|September 7, 2019
Biogeochemical controls of surface ocean phosphateAdam C Martiny, Michael W Lomas, Weiwei Fu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 15, 2020
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world settingTakuya Sho, Goki Suda, Koji Ogawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Pageof 7